The Signal Transduction Pathway Underlying Ion Channel Gene Regulation by Sp1-c-Jun Interactions*

Irena N. MelnikovaDagger and Paul D. Gardner§

From the Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts 01613

Received for publication, November 28, 2000, and in revised form, March 21, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

During neuronal differentiation, an exquisitely controlled program of signal transduction events takes place, leading to the temporally and spatially regulated expression of genes associated with the differentiated phenotype. A critical class of genes involved in this phenomenon is that made up of genes encoding neurotransmitter-gated ion channels that play a central role in signal generation and propagation within the nervous system. We used the well established PC12 cell line to investigate the molecular details underlying the expression of the neuronal nicotinic acetylcholine receptor class of ion channels. Neuronal differentiation of PC12 cells can be induced by nerve growth factor, leading to an increase in neuronal nicotinic acetylcholine receptor gene expression. Nerve growth factor initiates several signal transduction cascades. Here, we show that the Ras-dependent mitogen-activated protein kinase and phosphoinositide 3-kinase pathways are critical for the nerve growth factor-mediated increase in the transcriptional activity of a neuronal nicotinic acetylcholine receptor gene promoter. In addition, we show that a component of the Ras-dependent mitogen-activated protein kinase pathway, nerve growth factor-inducible c-Jun, exerts its effects on receptor gene promoter activity most likely through protein-protein interactions with Sp1. Finally, we demonstrate that the target for nerve growth factor signaling is an Sp1-binding site within the neuronal nicotinic acetylcholine receptor gene promoter.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nerve growth factor (NGF)1 is critical for the survival and differentiation of sensory and sympathetic neurons in the peripheral nervous system (1) and of basal forebrain and hippocampal cholinergic neurons in the central nervous system (2). NGF signals through binding to its receptors, a high affinity tyrosine kinase receptor, TrkA, and a low affinity receptor, p75 (3). Binding of NGF to its receptors initiates several signal transduction cascades, including, among others, ras-dependent mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3-K), and the cAMP-dependent protein kinase pathways (3). Some of the downstream targets of the activated protein kinase pathways are transcription factors such as AP-1, cAMP responsive element-binding protein, and NF-kappa B.

Rat pheochromocytoma PC12 cells have been extensively used to study the molecular mechanisms involved in NGF signaling. PC12 cells are chromaffin-like cells that in response to NGF treatment withdraw from the cell cycle and differentiate into sympathetic-like neurons, a process accompanied by neurite outgrowth, increased electrical excitability, and changes in neurotransmitter synthesis (4-6). Among the signal transduction cascades activated by NGF in PC12 cells, the MAPK and the PI3-K pathways are thought to play a central role, although other pathways are clearly important (7-10). Activated TrkA promotes conversion of the membrane-anchored Ras-GDP into Ras-GTP. Ras then cooperates in activation of a serine/threonine kinase, Raf-1, which phosphorylates the dual specificity MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK), which in turn phosphorylates and activates the ERKs, ERK1 and ERK2. Recently, it was demonstrated that activation of ERK in response to NGF in both primary sensory neurons and in PC12 cells also requires activation of the PI3-K pathway (11, 12). PI3-K is required for internalization of TrkA and for its signaling to ERK via a Ras family member, Rap 1 (11, 12). Rapid activation of ERK in response to NGF is mediated through Ras, whereas the sustained activation is Rap 1-dependent (11). Activation of ERK is thought to be required for PC12 responsiveness to NGF, because NGF-induced differentiation can be blocked by specific kinase inhibitors, by antibodies against Ras and MEK, or by expression of dominant negative mutants of Ras and MEK (13-16). In addition, constitutively active forms of Ras, Raf-1, and MEK1 can induce neuronal differentiation of PC12 cells (15, 17-19). Activated ERKs translocate to the nucleus, where they phosphorylate and activate the existing transcription factor c-Jun, as well as induce expression of c-Jun (20). Interestingly, overexpression of activated c-Jun in PC12 cells induces neurite outgrowth, suggesting that c-Jun plays an important role in promoting PC12 neural differentiation (20).

Among the neuronal genes whose expression is up-regulated in response to NGF in PC12 cells are the genes encoding several subunits (alpha 3, alpha 5, alpha 7, beta 2, and beta 4) of neuronal nicotinic acetylcholine receptors (nAChRs) (21-23). nAChRs are pentameric ligand-gated ion channels important for synaptic transmission in the nervous system (24). Previously, we demonstrated that the NGF-mediated increase in nAChR gene expression is independent of cAMP-dependent protein kinase signaling (21) and that NGF treatment of PC12 cells increases the transcriptional activity of the beta 4 gene promoter (25). In this study we investigated the involvement of the other NGF-signaling pathways, namely MAPK, PI3-K, protein kinase C, and phospholipase C, in the regulation of nAChR gene expression. We show that in PC12 cells, activation of PI3-K and one of the components of the MAPK pathway, MEK, is important for up-regulation of beta 4 subunit gene promoter activity in response to NGF. We also show that NGF-inducible c-Jun can transactivate the promoter of the beta 4 gene through cooperation with Sp1 protein bound to the beta 4 promoter at a previously identified Sp1-binding site, a CA box. We further demonstrate that this Sp1-binding site is necessary for the responsiveness of the beta 4 promoter to NGF.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Transfections-- SN17 cells (26) and Drosophila melanogaster Schneider SL2 cells were maintained as described (27, 28). PC12 cells (29) were cultured and differentiated with NGF (Upstate Biotechnology, Lake Placid, NY) as previously described (25). Twenty-four h prior to transfections, SN17 cells were plated at a density of 250,000 cells per 35-mm dish. Transfections were performed by a calcium phosphate method using a commercially available kit (Eppendorf-5 Prime, Inc., Boulder, CO). The wild type rat beta 4-luciferase expression plasmid, pX1B4FH, containing a 226-bp FokI/HindIII fragment spanning nucleotides -89 to +137, relative to the beta 4 transcription initiation site, and the construct pX1B4FHmut4, containing a mutation in the CA box of the beta 4 promoter, were described previously (25, 30). Cells were transfected with 2.5 µg of test DNA (pX1B4FH or pX1B4FHmut4), 2.5 µg of effector DNA (the empty pCMV5 vector (Invitrogen, Carlsbad, CA) or pCMV-jun constructs), and 2.5 µg of a beta -galactosidase expression vector, RSV-beta gal. In some cases, no effector DNA was included in the transfections. To ensure that the calcium phosphate/DNA precipitates had equal amounts of DNA, appropriate quantities of pBluescript II SK DNA (Stratagene, La Jolla, CA) were added to each sample. PC12 cells were transfected in 60-mm dishes at a density of 106 cells/ml using 30 µl of LipofectAMINE (2 mg/ml; Life Technologies, Inc.) and 2.5 µg of each DNA. After a 5-h incubation in the lipid/DNA mix, cells were washed twice with Dulbecco's modified Eagle's medium and fed with growth medium. For experiments involving the pharmacological kinase inhibitors, growth media were supplemented with or without 100 ng/ml NGF and with or without inhibitors, as indicated. All inhibitors were purchased from Calbiochem (San Diego, CA) and were used at the following concentrations: MEK inhibitor PD98059 at 100 µM (31), PI3-K inhibitor LY294002 at 50 µM (12, 32), phospholipase C inhibitor U-73122 at 1 µM (33), and protein kinase C inhibitors calphostin C (33) and bisinodylmalemide (BIM) (34) at 400 nM and 1 µM, respectively. SL2 cells were transfected as previously described (28), except that 100 ng of the effector DNAs (pActSp1 or pPacJun) were used. The pPacJun plasmid was a kind gift of Dr. J. Noti and is described elsewhere (35). Forty-eight h following transfection, cells were harvested and assayed for luciferase activity using a commercially available kit (Promega Corp., Madison, WI) and an Autolumat LB953 luminometer (EG&G Berthold, Gaithersburg, MD). All transfections were done a minimum of two times with two different preparations of plasmid DNAs. To correct for differences in transfection efficiencies between dishes, the luciferase activity in each sample was normalized to the beta -galactosidase activity in the same sample, which was measured using a commercially available kit (Galacto-Light; Tropix, Inc., Bedford, MA).

Immunoprecipitations and Western Blotting-- Immunoprecipitations and Western blotting were performed as previously described (36) using 250 µg of nuclear extracts prepared from NGF-treated PC12 cells. Anti-c-Jun rabbit polyclonal antibody was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Nuclear extracts were prepared by the method of Dignam et al. (37) as previously described (38), except that nuclear extracts were dialyzed against RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PI3-K and MEK Activation Are Necessary for the Induction of the beta 4 Promoter in Response to NGF-- NGF-dependent up-regulation of neuronal nAChR gene expression in PC12 cells is thought to occur partly at the level of transcription (25). To investigate which of the NGF-activated pathways is involved in the transcriptional regulation of neuronal nAChR gene expression in PC12 cells, we examined the effects of blocking several of these pathways on the transcriptional activity of the beta 4 gene promoter. We previously identified a 226-bp promoter fragment of the beta 4 gene that can confer neuron-specific expression to a reporter gene in transient transfection assays (27). We have also demonstrated that treatment of PC12 cells with NGF results in a significant increase in beta 4 promoter activity and that the 226-bp region is sufficient to mediate this response (25, 27). We therefore investigated whether MEK, PI3-K, protein kinase C, or phospholipase C is involved in the regulation of transcription of the beta 4 gene through elements in the 5' regulatory region of the gene. The 226-bp beta 4 fragment fused upstream of the luciferase gene (pX1B4FH) was transiently transfected into PC12 cells. Following transfection cells were treated with NGF for 36 h. A parallel set of transfected cells was left untreated and served as a control. Consistent with our previous results, 36 h of NGF treatment stimulated beta 4 promoter activity and resulted in induction of reporter gene activity (Fig. 1). When NGF treatment of the transfected cells was carried out in the presence of PD98059, a selective pharmacological agent that blocks activation of MEK, or LY294002, a specific pharmacological inhibitor of PI3-K, stimulation of the beta 4 promoter was significantly reduced, as judged by reporter gene activity (Fig. 1). In contrast, inhibitors of phospholipase C, U-73122, and protein kinase C, calphostin C, and bisinodylmalemide, had little effect on the activity of the beta 4 promoter in transfected cells in response to NGF (Fig. 1). These results suggest that activation of the beta 4 promoter in response to NGF is mediated in part via the MAPK- and PI3-K-dependent pathways in PC12 cells. This is consistent with a model suggesting that these two pathways share overlapping functions in neuronal cells (12). In addition, these data indicate that the 226-bp fragment of the beta 4 promoter contains the necessary elements to mediate the response to ERK activation, a common downstream target of MEK and PI3-K (12).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Pharmacological blockade of MEK and PI3-K prevents NGF activation of the beta 4 promoter. PC12 cells were transiently transfected with pX1B4FH as described under "Experimental Procedures." Following transfection, cells were treated with 100 ng/ml NGF in the presence or absence of specific pharmacological kinase inhibitors for 36 h, as indicated. Luciferase values were normalized to beta -galactosidase expression as driven by the CMV promoter (see "Experimental Procedures"). Fold induction was calculated relative to the normalized luciferase activity obtained from transfected cells that were not treated with NGF. Error bars represent standard deviations of the means. PD, PD98059; LY, LY294002; U, U-73122; CalC, calphostin C.

c-Jun Transcativates the beta 4 Promoter in PC12 and SN17 Cells-- It is well established that in PC12 cells, activation of the ERK cascade by NGF induces c-Jun expression and phosphorylation of its gene product (20). c-Jun is a transcription factor that has been implicated in regulation of gene expression in response to multiple extracellular stimuli (39). To address the question whether c-Jun is capable of regulating the activity of the beta 4 promoter, PC12 cells were transiently transfected with the 226-bp beta 4 promoter-luciferase construct, pX1B4FH, alone or in combination with an expression construct for c-Jun, pCMV-jun, in which the c-Jun gene is under the control of the CMV promoter, or with an empty parental vector, pCMV5. As shown in Fig. 2A (left side), transfections of the empty expression vector pCMV5 had no effect on reporter gene activity. However, when the beta 4-luciferase construct was cotransfected with c-Jun, a dramatic increase in reporter gene activity was observed (Fig. 2A). Similar results were observed in the cholinergic cell line SN17 (Fig. 2B). Together, these data indicate that, indeed, c-Jun is capable of transactivating the beta 4 promoter and suggest that c-Jun-responsive elements are present within this 226-bp fragment of the beta 4 promoter.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   c-Jun transactivates the beta 4 promoter through an Sp1-binding site. PC12 cells (A) or SN17 cells (B) were transfected with either the wild type beta 4 promoter/luciferase construct (WT) (pX1B4FH) or the mutant construct (mut) (pX1B4FHmut4) alone or with pCMV5 or pCMV-jun (c-Jun). Luciferase values were normalized to beta -galactosidase expression as driven by the CMV promoter. Error bars represent standard deviations of the means.

Jun proteins bind to the DNA sequence 5'-TGACTCA-3', referred to as an AP-1 site, as homodimers or as heterodimers with Fos proteins (39). Interestingly, sequence analysis of the beta 4 promoter fragment used in these experiments indicates that there are no AP-1-binding sites within this region. It is therefore possible that c-Jun transactivates the beta 4 promoter through protein-protein interactions with a factor that can bind to beta 4 regulatory elements.

c-Jun and Sp1 Physically Interact in PC12 Cells-- c-Jun has been shown to functionally interact with a number of transcription factors, including members of the Sp family, Sp1 and Sp3 (35, 40-42). Moreover, c-Jun can directly interact with Sp1 in vitro (41). This is particularly relevant to the beta 4 promoter, because we previously reported that both Sp1 and Sp3 can efficiently transactivate this promoter (28, 30, 36). Therefore, it is possible that c-Jun activates the beta 4 promoter through protein-protein interactions with Sp1 and/or Sp3. To test this hypothesis, we first wanted to address the question of whether c-Jun and Sp1 are physically associated in PC12 cells. To that end, we performed immunoprecipitation experiments followed by Western blot analysis. Anti-Sp1 or anti-c-Jun antiserum was used to immunoprecipitate proteins from nuclear extracts prepared from NGF-treated PC12 cells. The precipitated proteins were separated via SDS-polyacrylamide gel electrophoresis and blotted onto a nitrocellulose membrane that was subsequently incubated with anti-Sp1 or anti-c-Jun antiserum. As shown in Fig. 3, preimmune serum did not precipitate either Sp1 or c-Jun in this experiment. However, complexes containing Sp1 and c-Jun were detected by immunoprecipitations using antibodies directed toward one or the other protein (Fig. 3). It should be noted that the levels of Sp1 found in c-Jun immunoprecipitates were somewhat lower when compared with those precipitated with anti-Sp1 antibody (Fig. 3), suggesting that not all cellular Sp1 is engaged in a complex with c-Jun. The same was true with c-Jun as well (Fig. 3). These data provide compelling evidence for direct physical interactions between Sp1 and c-Jun in PC12 cells and support the idea that c-Jun may regulate the beta 4 promoter through its association with Sp1.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   Immunoprecipitations of c-Jun-Sp1 complexes from NGF-treated PC12 cell lysates. Anti-c-Jun, anti-Sp1, or preimmune rabbit serum (PIRS) was used to immunoprecipitate (IP) proteins from a PC12 cell extract. Western analysis of the immunoprecipitated material was carried out using anti-Sp1 or anti-c-Jun antiserum as indicated.

c-Jun Transcativates the beta 4 Promoter through an Sp1-binding Site-- Previously, we showed that Sp1 can specifically bind to a CA box in the 226-bp region of the beta 4 promoter (30, 36) and that this interaction is critical for Sp-mediated transactivation of the beta 4 promoter (36). If c-Jun activates the beta 4 promoter through its association with Sp1, then the Sp1-binding site within this promoter, the CA box, should be important for the ability of c-Jun to regulate the beta 4 promoter. To test this hypothesis, PC12 cells were cotransfected with a wild type beta 4 promoter-luciferase expression construct, pX1B4FH, or with a construct in which the CA box is mutated at three nucleotide positions, pX1B4FHmut4, and with an expression construct for c-Jun, pCMV-jun. As mentioned earlier, c-Jun was able to strongly transactivate the wild type beta 4 promoter, pX1B4FH (Fig. 2A). However, when the beta 4 promoter-luciferase reporter containing mutations in the CA box, pX1B4FHmut4, was used in this experiment, c-Jun activation of the promoter was marginal (Fig. 2A). Similar results were obtained from transfections performed in SN17 cells (Fig. 2B). Thus, the CA box appears to be critical for c-Jun-mediated transactivation of the beta 4 promoter.

c-Jun and Sp1 Synergistically Activate the beta 4 Promoter in Drosophila SL2 Cells-- To further investigate the importance of c-Jun-Sp1 interactions for the transactivation of the beta 4 promoter, we performed transfection experiments using the Drosophila SL2 cell line. These cells lack endogenous Sp1 activity (43-46), as well as endogenous c-Jun activity (35), making them a useful system to study the functional consequences of the protein-protein interactions mentioned above. We previously reported that Sp1 can strongly transactivate the beta 4 promoter when transfected into SL2 cells (28, 30, 36). To determine whether c-Jun activates the beta 4 promoter through its interactions with Sp1, SL2 cells were cotransfected with a wild type beta 4 promoter-luciferase expression construct (pX1B4FH) and pActSp1 or pPacJun or both. To confirm that Sp1 and c-Jun expression was involved in transactivation, the reporter DNA was also transfected with the parental vectors devoid of Sp1 and c-Jun coding sequences, pAct and pPacO, alone. As expected, Sp1 was capable of transactivating the wild type beta 4 promoter-luciferase construct ~20-fold (Fig. 4). Consistent with the observation that the beta 4 promoter fragment used in these experiments does not contain an AP-1-binding site, c-Jun by itself did not have any effect on reporter gene activity (Fig. 4). However, when Sp1 and c-Jun were cotransfected with the beta 4 promoter-luciferase construct, an ~120-fold increase in reporter gene activity was observed, indicating a synergistic effect of the two regulatory factors (Fig. 4). These results are consistent with the hypothesis that c-Jun activates the beta 4 promoter through direct interactions with Sp1.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Sp1 and c-Jun synergistically transactivate the beta 4 promoter in Drosophila cells. Drosophila SL2 cells were transfected with pX1B4FH or pX1B4FHmut4 (WT or mut, respectively) alone, with "empty" expression vectors (pAct, pPacO), or with expression constructs for c-Jun and Sp1, individually and together. Fold induction was calculated as above.

To investigate the importance of the Sp1-binding site for the ability of Sp1 and c-Jun to synergistically activate the beta 4 promoter, similar transfection experiments were performed using a beta 4 promoter-luciferase construct in which the CA box is mutated at three nucleotide positions (pX1B4FHmut4). Mutation in this site reduces the ability of Sp1 to transactivate the beta 4 promoter in SL2 cells (Fig. 4) (36). The residual activation seen with the mutated promoter is most likely a result of Sp1 binding to downstream low affinity Sp-binding sites (30, 36). As in the case of the wild type beta 4 promoter, c-Jun was unable to transactivate the mutated promoter (Fig. 4). Synergistic transactivation of the wild type beta 4 promoter by Sp1 and c-Jun was dramatically reduced when the mutated promoter was used. The observed reporter gene activity was comparable with that of Sp1 alone on the wild type promoter (Fig. 4). Together, these results indicate that Sp1 and c-Jun can cooperate to activate the beta 4 promoter in Drosophila cells and that an intact Sp1-binding site is important for this cooperativity.

The CA Box Is Important for the NGF Responsiveness of the beta 4 Promoter in PC12 Cells-- Collectively, the data presented above suggest that the CA box of the beta 4 promoter might be a target for NGF signaling in PC12 cells. To address this question, we transfected PC12 cells with a wild type beta 4 promoter-luciferase expression construct, pX1B4FH, or with the construct in which the CA box is mutated, pX1B4FHmut4. Consistent with our previous findings (30), the basal activity of the mutant promoter was significantly lower than that of the wild type in untreated PC12 cells (Fig. 5). Thirty-six h of NGF treatment of the transfected cells resulted in a dramatic increase in the activity of the wild type beta 4 promoter, as judged by reporter gene activity (Fig. 5). However, activity of the mutated promoter was increased only slightly, resulting in reporter gene activity similar to that produced by the wild type beta 4 promoter in unstimulated PC12 cells (Fig. 5). These data suggest that the CA box is necessary, but probably not sufficient, to mediate the response of the beta 4 promoter to NGF in PC12 cells.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   Mutation of the Sp1-binding site prevents NGF activation of the beta 4 promoter. PC12 cells were transfected with pX1B4FH (WT) or pX1B4FHmut4 (mut). Following transfection, cells were treated with 100 ng/ml NGF for 36 h. A parallel set of cells was left untreated. Luciferase values were normalized to beta -galactosidase expression as driven by the CMV promoter. Error bars represent standard deviations of the means.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

To date, twelve genes (alpha 2-alpha 10, beta 2-beta 4) encoding subunits of neuronal nAChRs have been identified. Assembly of the different subunits into pentameric homo- or heteromeric receptors results in formation of ion channels with distinct physiological and pharmacological profiles (24). This diversity is thought to be a consequence of differential expression of the subunit genes and subsequent incorporation of their respective products into mature receptors (47). Whereas the implications of the functional diversity of nAChR are beginning to be understood, relatively little is known regarding regulation of their gene expression in general and in response to neurotrophin signaling in particular. NGF-driven differentiation of PC12 cells has been extensively used as a model system to study the physiological, biochemical, and molecular mechanisms of neurotrophin signaling. In regard to neuronal nAChR, it has been demonstrated that in PC12 cells, NGF increases ACh-induced channel activity and ACh-induced macroscopic current density (4, 21, 48), phenomena that are thought to be a consequence of an increase in the number of functional nAChR (21). This hypothesis is consistent with observed increases in the binding of [3H]nicotine (49) and of anti-nAChR antibodies (50) that occur in PC12 cells in response to NGF. Whereas the exact mechanisms of the increase in the number of nAChRs are unknown, NGF-driven induction of nAChR gene expression is clearly important (21). Previously, we showed that the NGF-induced up-regulation of nAChR expression and increases in ACh-induced current density are independent of cAMP-dependent protein kinase activity (21). In this study, using specific chemical inhibitors, we demonstrate that the MAPK and PI3-K signal transduction cascades, but not the phospholipase C or protein kinase C pathways, are important for NGF-mediated induction of the promoter of the beta 4 subunit gene in PC12 cells. Significantly, positive stimulation of beta 4 promoter activity in response to NGF was considerably reduced by the addition of a pharmacological inhibitor of MEK, PD98059, and was reduced to a similar extent by addition of a PI3-K inhibitor, LY294002. These data suggest that activation of the MAPK and PI3-K pathways is clearly necessary for the induction of nAChR gene expression. Moreover, they indicate that MAPK and PI3-K pathways might have common downstream targets in PC12 cells. Originally, PI3-K and MAPK were thought to initiate two distinct signal transduction cascades in neuronal cells. However, in a recent report York et al. (12) convincingly demonstrated that inhibitors of PI3-K block well known targets of the MAPK pathway, namely ERK and B-Raf, therefore indicating that the MAPK and PI3-K pathways are indeed interconnected.

The MAPK pathway, through a series of phosphorylation events (that include phosphorylation of ERK), is thought to relay signals received by NGF receptors in the plasma membrane to specific transcription factors in the nucleus (51). These activated transcription factors are required for expression of the delayed early and late genes, some of which, such as neuronal nAChR, contribute to the neuronal phenotype developed by PC12 cells in response to NGF. c-Jun is believed to be one of the key factors activated by the MAPK signaling cascade (39). c-Jun is an inducible transcription factor that is activated in response to multiple extracellular stimuli, including growth factors, cytokines, neurotransmitters, T cell activators, various forms of stress, and UV radiation (39). Regulation of c-Jun activity occurs at the level of transcription, resulting in an increase in c-Jun mRNA, as well as post-transcriptionally, resulting in an enhancement of its transactivation potential through phosphorylation (39). Leppa et al. (20) recently demonstrated that in PC12 cells, activation of the MAPK pathway, more specifically ERK, results in stimulation of both c-Jun synthesis and phosphorylation. Moreover, they showed that an exogenous activated form of c-Jun induced marked neurite outgrowth and that overexpression of wild type c-Jun potentiated differentiation induced by MEK1, whereas dominant-negative mutants of c-Jun inhibited it (20). Thus, proper c-Jun activation appears to be necessary for neuronal differentiation of PC12 cells. We therefore investigated whether c-Jun is capable of regulating the promoter of the beta 4 subunit gene. Using the same fragment of the beta 4 promoter that confers neuron-specific expression to a reporter gene (24) and that is sufficient to mediate responses to NGF in PC12 cells (25), we showed that c-Jun can strongly transactivate the beta 4 promoter in both PC12 and SN17 cells. Surprisingly, this 226-bp region of the beta 4 promoter does not contain "classic" Jun-binding sites, AP-1 elements, to which c-Jun normally binds as a dimer with Jun-Fos proteins (52). Thus, we hypothesized that c-Jun transactivates the beta 4 promoter through protein-protein interactions with a nuclear factor bound to beta 4 regulatory elements.

c-Jun has been shown to directly interact with a number of transcription factors, for example, members of the cAMP responsive element-binding protein family, glucocorticoid receptor (53), Smad proteins (54, 55), and members of the Sp family, Sp1 and Sp3 (35, 40-42). Interestingly, we have previously demonstrated that both Sp1 and Sp3 can strongly transactivate the beta 4 promoter (28, 30, 36). Sp1 and Sp3 are zinc finger DNA-binding proteins that bind a CA box element in the 226-bp region of the beta 4 promoter (30, 36). Originally, Sp family members were thought to be ubiquitous factors contributing to core promoter activities (56). However, more recently, they have been shown to participate in regulated and cell type-specific gene expression, including regulation of transcription of a number of neuron-specific genes (30, 36, 57-62). Moreover, in PC12 cells, NGF treatment has been shown to stimulate Sp1-dependent transcription (63). Although the exact mechanism of this stimulation is unknown, it is thought that post-translational modifications and/or association with other factors may play a role (63). Hence, NGF-induced activation of beta 4 gene expression may occur through functional interactions between c-Jun and Sp1. Consistent with this idea are results of our immunoprecipitation/Western blot analysis demonstrating that c-Jun and Sp1 can physically associate in NGF-treated PC12 cells. Furthermore, the Sp1-binding site in the 226-bp region of the beta 4 promoter, a CA box, is important for the ability of c-Jun to transactivate this promoter in both PC12 and SN17 cells. In contrast to PC12 and SN17 cells, c-Jun by itself had no effect on reporter gene activity in Drosophila SL2 cells that were devoid of endogenous Sp proteins. c-Jun was able to transactivate the beta 4 promoter in SL2 cells only when cotransfected with Sp1, providing additional support for the hypothesis that it does so through direct interactions with the latter protein. Interestingly, transactivation by c-Jun and Sp1 occurred in a synergistic manner and did so in a CA box-dependent manner. Together, these data suggest that Sp1 and c-Jun can cooperate to activate the beta 4 promoter and that an intact Sp1-binding site is important for this cooperativity. Moreover, the CA box of the beta 4 promoter appears to be critical for NGF signaling, because the responsiveness of the beta 4 promoter to NGF is dramatically reduced when the CA box is mutated. Previous studies demonstrated that c-Jun and Sp1 functionally interact on both synthetic and natural promoters (40, 41); however, to our knowledge, this study is the first demonstration of cooperativity of these proteins in neuronal cells. Whether, similar to Sp1, Sp3 can functionally interact with c-Jun to regulate nAChR gene expression remains to be elucidated.

It should be noted that the beta 4 subunit, together with the alpha 3 and alpha 5 subunits, forms the predominant neuronal nAChR subtype expressed in the peripheral nervous system (64, 65). These three genes are tightly clustered in mammalian genomes, raising the possibility that they are coordinately expressed via a common regulatory mechanism. Indeed, it has been demonstrated that Sp1 is important for the regulation of expression of all three genes (30, 36, 61, 62). Therefore, it is possible that through interactions with Sp1, c-Jun might regulate the promoters of the alpha 3 and alpha 5 subunit genes as well.

    ACKNOWLEDGEMENTS

We thank John Noti, Mangkey Bounpheng, Barbara Christy, Ed Seto, and Haley Melikian for expression constructs and useful discussions. A portion of the work described was performed at the University of Texas Health Science Center at San Antonio.

    FOOTNOTES

* This work was supported in part by grants from the National Institutes of Health and the Smokeless Tobacco Research Council, Inc. (to P. D. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a POWRE grant from The National Science Foundation.

§ To whom correspondence should be addressed: Brudnick Neuropsychiatric Research Inst., Dept. of Psychiatry, University of Massachusetts Medical School, 55 Lake Ave. North, P.O. Box 2795, Worcester, MA 01613. Tel.: 508-856-4035; Fax: 508-856-4130; E-mail: paul.gardner@umassmed.edu.

Published, JBC Papers in Press, March 21, 2001, DOI 10.1074/jbc.M010735200

    ABBREVIATIONS

The abbreviations used are: NGF, nerve growth factor; MAPK, ras-dependent mitogen-activated protein kinase; PI3-K, phosphoinositide 3-kinase; ERK, extracellular signal-regulated kinase; MEK, MAPK/ERK kinase; ACh, acetylcholine; nAChR, neuronal nicotinic acetylcholine receptor; bp, base pair.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kaplan, D., Zirrgiebel, U., and Atwal, J. (2000) Neuron 25, 253-254[Medline] [Order article via Infotrieve]
2. Ruberti, F., Capsoni, S., Comparini, A., Di Daniel, E., Franzot, J., Gonfloni, S., Rossi, G., Berardi, N., and Cattaneo, A. (2000) J. Neurosci. 20, 2589-2601[Abstract/Free Full Text]
3. Friedman, W. J., and Greene, L. A. (1999) Exp. Cell Res. 253, 131-142[CrossRef][Medline] [Order article via Infotrieve]
4. Dichter, M. A., Tischler, A. S., and Greene, L. A. (1977) Nature 268, 501-504[Medline] [Order article via Infotrieve]
5. Greene, L. A., and Tischler, A. S. (1982) Adv. Cell. Neurobiol. 3, 373-414
6. Halegoua, S., Armstrong, R. C., and Kremer, N. E. (1991) Curr. Top. Microbiol. Immunol. 165, 119-170[Medline] [Order article via Infotrieve]
7. Kalman, D., Wong, B., Horvai, A. E., Cline, M. J., and O'Lague, P. H. (1990) Neuron 4, 355-366[Medline] [Order article via Infotrieve]
8. Fanger, G. R., Erhardt, P., Cooper, G. M., and Maue, R. A. (1993) J. Neurochem. 61, 1977-1980[Medline] [Order article via Infotrieve]
9. Obermeier, A., Bradshaw, R. A., Seedorf, K., Choidas, A., Schlessinger, J., and Ullrich, A. (1994) EMBO J. 13, 1585-1590[Abstract]
10. Stephens, R. M., Loeb, D. M., Copeland, T. D., Pawson, T., Greene, L. A., and Kaplan, D. R. (1994) Neuron 12, 691-705[Medline] [Order article via Infotrieve]
11. York, R. D., Yao, H., Dillon, T., Ellig, C. L., Eckert, S. P., McCleskey, E. W., and Stork, P. J. (1998) Nature 392, 622-626[CrossRef][Medline] [Order article via Infotrieve]
12. York, R. D., Molliver, D. C., Grewal, S. S., Stenberg, P. E., McCleskey, E. W., and Stork, P. J. (2000) Mol. Cell. Biol. 20, 8069-8083[Abstract/Free Full Text]
13. Kremer, N. E., D'Arcangelo, G., Thomas, S. M., DeMarco, M., Brugge, J. S., and Halegoua, S. (1991) J. Cell Biol. 115, 809-819[Abstract]
14. Thomas, S. M., DeMarco, M., D'Arcangelo, G., Halegoua, S., and Brugge, J. S. (1992) Cell 68, 1031-1040[Medline] [Order article via Infotrieve]
15. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. (1994) Cell 77, 841-852[Medline] [Order article via Infotrieve]
16. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 13585-13588[Abstract/Free Full Text]
17. Bar-Sagi, D., and Feramisco, J. R. (1985) Cell 42, 841-848[Medline] [Order article via Infotrieve]
18. Noda, M., Ko, M., Ogura, A., Liu, D. G., Amano, T., Takano, T., and Ikawa, Y. (1985) Nature 318, 73-75[Medline] [Order article via Infotrieve]
19. Wood, K. W., Qi, H., D'Arcangelo, G., Armstrong, R. C., Roberts, T. M., and Halegoua, S. (1993) Proc. Natl. Acad. Sci. U. S. A.  90, 5016-5020[Abstract]
20. Leppa, S., Saffrich, R., Ansorge, W., and Bohmann, D. (1998) EMBO J. 17, 4404-4413[Abstract/Free Full Text]
21. Henderson, L. P., Gdovin, M. J., Liu, C., Gardner, P. D., and Maue, R. A. (1994) J. Neurosci. 14, 1153-1163[Abstract]
22. Boyd, R. T. (1996) Neurosci. Lett. 208, 73-76[CrossRef][Medline] [Order article via Infotrieve]
23. Nakayama, H., Ueno, S., Ikeuch, I. T., and Hatanaka, H. (2000) J. Neurochem. 74, 1346-1354[CrossRef][Medline] [Order article via Infotrieve]
24. Cordero-Erausquin, M., Marubio, L. M., Klink, R., and Changeux, J. P. (2000) Trends Pharmacol. Sci. 21, 211-217[CrossRef][Medline] [Order article via Infotrieve]
25. Hu, M., Whiting-Theobald, N. L., and Gardner, P. D. (1994) J. Neurochem. 62, 392-395[Medline] [Order article via Infotrieve]
26. Hammond, D. N., Lee, H. J., Tonsgard, J. H., and Wainer, B. H. (1989) Brain Res. 512, 190-200
27. Liu, Q., Melnikova, I. N., Hu, M., and Gardner, P. D. (1999) J. Neurosci. 19, 9747-9755[Abstract/Free Full Text]
28. Du, Q., Melnikova, I. N., and Gardner, P. D. (1998) J. Biol. Chem. 273, 19877-19883[Abstract/Free Full Text]
29. Greene, L. A., and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428[Abstract]
30. Bigger, C. B., Casanova, E. A., and Gardner, P. D. (1996) J. Biol. Chem. 271, 32842-32848[Abstract/Free Full Text]
31. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A.  92, 7686-7689[Abstract]
32. Zheng, W.-H., Kar, S., and Quirion, R. (2000) J. Biol. Chem. 275, 39152-39158[Abstract/Free Full Text]
33. Kolkova, K., Novitskaya, V., Pedersen, N., Berezin, V., and Bock, E. (2000) J. Neurosci. 20, 2238-2246[Abstract/Free Full Text]
34. Melikina, H. E., and Buckley, K. M. (1999) J. Neurosci. 19, 7699-7710[Abstract/Free Full Text]
35. Noti, J. D. (1997) J. Biol. Chem. 272, 24038-24045[Abstract/Free Full Text]
36. Bigger, C. B., Melnikova, I. N., and Gardner, P. D. (1997) J. Biol. Chem. 272, 25976-25982[Abstract/Free Full Text]
37. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract]
38. Melnikova, I. N., and Christy, B. A. (1996) Cell Growth Differ. 7, 1067-1079[Abstract]
39. Karin, M., Liu, Z., and Zandi, E. (1997) Curr. Opin. Cell Biol. 9, 240-246[CrossRef][Medline] [Order article via Infotrieve]
40. McDonough, P. M., Hanford, D. S., Sprenkle, A. B., Mellon, N. R., and Glembotski, C. C. (1997) J. Biol. Chem. 272, 24046-24053[Abstract/Free Full Text]
41. Kardassis, D., Papakosta, P., Pardali, K., and Moustakas, A. (1999) J. Biol. Chem. 274, 29572-29581[Abstract/Free Full Text]
42. Falvo, J. V., Uglialoro, A. M., Brinkman, B. M., Merika, M., Parekh, B. S., Tsai, E. Y., King, H. C., Morielli, A. D., Peralta, E. G., Maniatis, T., Thanos, D., and Goldfeld, A. E. (2000) Mol. Cell. Biol. 20, 2239-2247[Abstract/Free Full Text]
43. Courey, A. J., and Tjian, R. (1988) Cell 55, 887-898[Medline] [Order article via Infotrieve]
44. Courey, A. J., Holtzman, D. A., Jackson, S. P., and Tjian, R. (1989) Cell 59, 827-836[Medline] [Order article via Infotrieve]
45. Pascal, E., and Tjian, R. (1991) Genes Dev. 5, 1646-1656[Abstract]
46. Hagen, G., Muller, S., Beato, M., and Suske, G. (1994) EMBO J. 13, 3843-3851[Abstract]
47. Boyd, R. T. (1997) Crit. Rev. Toxicol. 27, 299-318[Medline] [Order article via Infotrieve]
48. Ifune, C. K., and Steinbach, J. H. (1990) Proc. Natl. Acad. Sci. U. S. A.  87, 4794-4798[Abstract]
49. Madhok, T. C., and Sharp, B. M. (1992) Endocrinology 130, 825-830[Abstract]
50. Whiting, P. J., Schoepfer, R., Swanson, L. W., Simmons, D. M., and Lindstrom, J. M. (1987) Nature 327, 515-518[CrossRef][Medline] [Order article via Infotrieve]
51. Klesse, L. J., and Parada, L. F. (1999) Microsc. Res. Tech. 45, 210-216[CrossRef][Medline] [Order article via Infotrieve]
52. Angel, P., and Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157[CrossRef][Medline] [Order article via Infotrieve]
53. Curran, P., and Vogt, P. (1992) in Transcriptional Regulation (McKnight, S. L. , and Yamamoto, K. R., eds) , pp. 1123-1146, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
54. Zhang, Y., Feng, X. H., and Derynck, R. (1998) Nature 394, 909-913[CrossRef][Medline] [Order article via Infotrieve]
55. Liberati, N. T., Shen, X., Datto, M. B., Frederick, J. P., and Wang, X.-F. (1999) Proc. Natl. Acad. Sci. U. S. A.  96, 4844-4849[Abstract/Free Full Text]
56. Courey, A. J., and Tjian, R. (1992) in Transcriptional Regulation (McKnight, S. L. , and Yamamoto, K. R., eds) , pp. 743-769, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
57. Chin, L. S., Li, L., and Greengard, P. (1994) J. Biol. Chem. 269, 18507-18513[Abstract/Free Full Text]
58. Faraonio, R., Minopoli, G., Porcellini, A., Costanzo, F., Cimino, F., and Russo, T. (1994) Nucleic Acids Res. 22, 4876-4883[Abstract]
59. Reeben, M., Neuman, T., Palgi, J., Palm, K., Paalme, V., and Saarma, M. (1995) J. Neurosci. Res. 40, 177-188[Medline] [Order article via Infotrieve]
60. Cibelli, G., Schoch, S., Pajunk, H., Brand, I. A., and Thiel, G. (1996) Eur. J. Biochem. 237, 311-317[Abstract]
61. Yang, X., Fyodorov, D., and Deneris, E. S. (1995) J. Biol. Chem. 270, 8514-8520[Abstract/Free Full Text]
62. Campos-Caro, A., Carrasco-Serrano, C., Valor, L. M., Viniegra, S., Ballesta, J. J., and Criado, M. (1999) J. Biol. Chem. 274, 4693-4701[Abstract/Free Full Text]
63. Yan, G. Z., and Ziff, E. B. (1997) J. Neurosci. 17, 6122-6132[Abstract/Free Full Text]
64. Conroy, W. G., Vernallis, A. B., and Berg, D. K. (1993) Neuron 9, 679-691
65. Conroy, W. G., and Berg, D. K. (1995) J. Biol. Chem. 270, 4424-4431[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.